Related Experiment Videos

Life-threatening bullous skin eruptions during interleukin-2 therapy

M R Staunton¹, M C Scully, P E Le Boit

¹Department of Medicine, University of California, San Francisco 94143-0128.

Journal of the National Cancer Institute

|January 2, 1991

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases.

Journal of cutaneous pathology·2000

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.

Clinical cancer research : an official journal of the American Association for Cancer Research·1997

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.

Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy·1994

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy·1994

Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens.

Journal of surgical oncology·1994

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1993

See all related articles